| 
             
						
						
						 India 
						to press drug firms to tackle cough syrup abuse 
			
   
            
			Send a link to a friend  
 
			
		[October 27, 2015] 
		By Aditya Kalra and Paritosh 
		Bansal 
			
		NEW DELHI (Reuters) - India plans to step 
		up pressure on pharmaceutical companies to better police supplies of 
		codeine-based cough syrups, concerned the firms have not yet fully 
		complied with directives more than a year old, a finance ministry 
		official said on Tuesday. 
             | 
        
        
            | 
             
			
			 The International Narcotics Control Board ranks the abuse of 
			medicines containing narcotics and their smuggling from India among 
			the "greatest drug-related challenges" facing South Asia. 
			 
			Codeine is a narcotic used in cough suppressants that are prone to 
			abuse by addicts, especially in neighboring Bangladesh, where it is 
			banned, though smuggled in from India. 
			 
			Since last year, Indian regulators have been privately asking drug 
			firms to make it easier for law enforcement officials to trace 
			smuggled cough syrup bottles back to wholesalers, a Reuters review 
			showed this month. 
			 
			In response, companies have cut the number of bottles produced in a 
			single batch, but have resisted other demands, such as selling a 
			single batch to one buyer and changing labeling procedures, the 
			review showed. 
			
			  
			Sales of the drug in India were "unusually" high in some states and 
			companies will again be asked to comply with new norms, said Rashmi 
			Verma, a senior official of the finance ministry, which controls 
			narcotics allocations. 
			 
			"We are going to put pressure on them," said Verma, adding that the 
			demand would be made at the ministry's next meeting with the drug 
			firms, probably before the end of the year. 
			 
			Verma did not give details of steps the ministry could take to 
			ensure compliance. She said the government had previously reduced 
			companies' allocation of codeine, distributed only through state-run 
			factories. 
			 
			U.S.-based Pfizer and Abbott Laboratories are leading players in 
			India's $103-million market for codeine-based cough syrups. The 
			Indian units of both companies did not respond to requests for 
			comment. 
			
            [to top of second column]  | 
            
             
  
				
			Drug companies say they have taken adequate steps to control the 
			abuse of such syrups. 
			 
			Industry executives also complain that compliance costs have 
			increased, and the measures demanded will swell costs and make 
			inventory harder to manage. 
			 
			India seized about 83,000 bottles of codeine-based cough syrup in 
			the six months through March. In Bangladesh, where the drug was 
			banned in the 1980s, about 750,000 bottles were seized last year. 
			 
			In July, drug regulators also considered a complete ban on such 
			syrups because of "rampant misuse", the minutes of one meeting of 
			regulators shows. 
			 
			The government does not want to ban the medicine, however, as there 
			is genuine demand for it, Verma added. 
			 
			(Editing by Clarence Fernandez) 
			[© 2015 Thomson Reuters. All rights 
				reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed. 
			
			  
			
			   |